Academics and practitioners join forces to solve the MIH puzzle

28 March, 2022 / infocus
 

One in seven children are affected by Molar Incisor Hypomineralisation (MIH) of one or more teeth. Yet, the precise aetiology is still unknown today. The current armamentarium has its limits and knowledge is often insufficient.

A group of experienced specialists from the academic field, paediatric and general practitioners gathered together at GC Europe’s campus to kick off a long-term collaboration, skilfully guided by chairman Professor Dr Norbert Krämer, University of Giessen, Germany, to unravel the conundrum that MIH has become.

MIH is affecting the quality of life of many children, who have to deal with chronic pain and hypersensitivity, aesthetic problems and more often than not, many visits from dentist to dentist. All participants confirmed that despite much interest in this topic from researchers, practitioners and patients and their parents, it still raises many questions. The aetiology seems to be complex and the clinical appearance shows a broad variation, which makes this phenomenon very hard to study.

Every aspect of this developmental dental disease was discussed, from pain and hypersensitivity control to emergency treatments and solutions and treatments for the short and long term. From current means, CPP-ACP (Recaldent™) plays a key role in tackling the hypersensitivity and remineralisation. Glass ionomers and stainless steel crowns are much valued tools in emergency and short-term treatments, whereas on a longer term, glass hybrids, composites and several types of indirect restorations come into play. Anaesthetics are unbearable and intraosseous infiltrations, nitrous oxide sedation and even general anaesthesia are all employed.

It has become quite clear that to find better solutions, research of a high level of quality and including a large population is needed. It is one of the stated goals of this MIH network. With this unique collaboration between well-known academics, pioneers in MIH and practitioners, the aim is to cover a large, widespread and representative study group that will be studied in a standardised way.

GC as a company has always taken much interest in this particular topic and is an active participant to keep developing solutions for dentists and patients regarding the treatment of MIH.

If you are interested in the unique clinical solutions that GC is already offering, please visit https://campaigns-gceurope.com/mih/ for product details, treatment plans, videos and webinars on the topic of MIH.

Categories: News

Comments are closed here.